Overview

Trial of Roflumilast in Asthma Management (TRIM)

Status:
Completed
Trial end date:
2021-07-30
Target enrollment:
Participant gender:
Summary
There are currently no treatments to specifically target asthma in obese adults. This pilot study is being conducted to investigate how effective roflumilast is in treating asthma in participants that have a higher BMI. Roflumilast can induce weight loss, which may lead to improved asthma control. The primary objective of TRIM is to perform a pilot placebo-controlled trial of roflumilast for the treatment of poorly controlled obese asthmatics.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
American Lung Association
National Heart, Lung, and Blood Institute (NHLBI)